Uncategorized

Denali climbs past Avlayah expectations with $3.6M in revenue

Published

on

After launching in April, Hunter syndrome drug Avlayah surprised analysts with a strong first quarter, as patients rush to get access to Denali Therapeutics’ new option.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version